Abstract
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have